5 completed, 1 active not recruiting, 1 unknown. 7 Phase 3, 1 Phase 2.
By phase and status
Follow midostaurin: new trials by email Literature Review of midostaurin trials Research Report on midostaurin
Trials (filtered) newest first · largest first
All 7 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance
Cytarabine, Daunorubicin, Midostaurin - Acute Myeloid Leukemia With FLT3/ITD Mutation | Phase 3 | Unknown | 172 | 2020-04-24 | 2022-03-02 |
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Gilteritinib, Midostaurin - Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 3 | Active not recruiting | 777 | 2019-12-20 | 2024-12-17 |
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
Crenolanib, Midostaurin, Cytarabine - Newly Diagnosed FLT3 Mutated AML | Phase 3 | Completed | 214 | 2018-08-15 | 2026-04-09 |
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
Midostaurin, Placebo, Chemotherapy - Acute Myeloid Leukemia (AML) | Phase 3 | Completed | 511 | 2018-07-20 | 2023-08-21 |
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
Midostaurin, Cytarabine, anthracycline ((daunorubicin or idarubicin): Induction Phase only - Acute Myeloid Leukemia | Phase 3 | Completed | 301 | 2018-02-13 | 2024-02-29 |
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Azacitidine, Cytarabine, Decitabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 / Phase 3 | Completed | 76 | 2018-02-02 | 2025-01-16 |
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
cytarabine, daunorubicin, midostaurin - Leukemia | Phase 3 | Completed | 717 | 2008-04-01 | 2026-10-21 |
Conditions studied
Leukemia, Myeloid, Acute (5) · Congenital Abnormalities (1) · GATA2 Deficiency (1) · Leukemia (1) · Leukemia, Basophilic, Acute (1) · Leukemia, Eosinophilic, Acute (1) · Leukemia, Erythroblastic, Acute (1) · Leukemia, Megakaryoblastic, Acute (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myelomonocytic, Acute (1) · Myelodysplastic Syndromes (1) · Neoplasm, Residual (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Sponsors
Novartis Pharmaceuticals (2) · Alliance for Clinical Trials in Oncology (1) · Arog Pharmaceuticals, Inc. (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · National Cancer Institute (NCI) (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1)
Countries
United States (4) · France (3) · Italy (3) · Norway (3) · Spain (3) · Australia (2) · Austria (2) · Belgium (2) · Bulgaria (2) · Czechia (2) · Finland (2) · Germany (2) · Lithuania (2) · Sweden (2) · Switzerland (2)
Top investigators
Laura C Michaelis (1) · M. Raaijmakers, Prof. Dr. (1) · Richard M. Stone, MD (1)
Results publications
PMID 22627678, PMID 28644114, PMID 30382485, PMID 31171508, PMID 31375516, PMID 33049054, PMID 36184192, PMID 37581981, PMID 41432755
NIH funding
2016 (1), 2017 (1), 2018 (1), U10CA180888 (1)